Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria

Trial Profile

XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Mar 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Urticaria
  • Focus Therapeutic Use
  • Acronyms XTEND-CIU
  • Sponsors Genentech
  • Most Recent Events

    • 25 Feb 2019 Results of post hoc analysis of XTEND-CIU analysing omalizumab treatment withdrawl after 24 and 48 weeks presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 23 May 2018 Results (n=134) assessing the impact of omalizumab on work productivity and activity impairment during double-blind period, presented at the 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
    • 19 Mar 2018 Results assessing validity, responsiveness and change of urticaria activity and impact measure (U-AIM) by using data from this study published in the Annals of Allergy, Asthma and Immunology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top